Neerav N Shukla

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8385835/publications.pdf

Version: 2024-02-01

44 papers	3,850 citations	394421 19 h-index	276875 41 g-index
44 all docs	44 docs citations	44 times ranked	9715 citing authors

#	Article	IF	Citations
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
2	Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways. Clinical Cancer Research, 2012, 18, 748-757.	7.0	203
3	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood, 2019, 134, 2361-2368.	1.4	190
4	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	21.4	152
5	Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. Clinical Cancer Research, 2019, 25, 6346-6356.	7.0	75
6	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	13.2	74
7	Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Children with Relapsed or Refractory MLL-r Acute Leukemia. Blood, 2016, 128, 2780-2780.	1.4	62
8	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374.	1.5	49
9	Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. Frontiers in Oncology, 2019, 9, 108.	2.8	49
10	DNA Methylationâ€“Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	3.0	37
11	Biomarkers in Ewing sarcoma: the promise and challenge of personalized medicine. A report from the Childrenâ€™s Oncology Group. Frontiers in Oncology, 2013, 3, 141.	2.8	36
12	Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	3.0	36
13	Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. Cancer Research, 2016, 76, 4525-4534.	0.9	33
14	Germline SDHA mutations in children and adults with cancer. Journal of Physical Education and Sports Management, 2018, 4, a002584.	1.2	33
15	A recurrent novel MGAâ€“NUTM1 fusion identifies a new subtype of high-grade spindle cell sarcoma. Journal of Physical Education and Sports Management, 2018, 4, a003194.	1.2	32
16	Cellâ€free DNA profiling in retinoblastoma patients with advanced intraocular disease: An MSKCC experience. Cancer Medicine, 2020, 9, 6093-6101.	2.8	32
17	Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatric Blood and Cancer, 2014, 61, 431-435.	1.5	30
18	Successful treatment of refractory metastatic histiocytic sarcoma with alemtuzumab. Cancer, 2012, 118, 3719-3724.	4.1	29

#	Article	IF	Citations
19	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. Cancer, 2020, 126, 3114-3121.	4.1	23
20	Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children/Young Adults with Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia. Transplantation and Cellular Therapy, 2022, 28, 72.e1-72.e8.	1.2	21
21	Germline BRCA2 mutations detected in pediatric sequencing studies impact parentsâ€™ evaluation and care. Journal of Physical Education and Sports Management, 2017, 3, a001925.	1.2	17
22	Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2018, 65, e26699.	1.5	16
23	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. Cancer Discovery, 2021, 11, 1424-1439.	9.4	16
24	Non-Hodgkinâ€™s lymphoma in children and adolescents. Current Oncology Reports, 2006, 8, 387-394.	4.0	15
25	Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study.. Journal of Clinical Oncology, 2022, 40, 10001-10001.	1.6	15
26	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. Molecular Cancer Research, 2021, 19, 1146-1155.	3.4	14
27	Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience. Leukemia and Lymphoma, 2018, 59, 1861-1870.	1.3	12
28	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusionâ€“Driven Cancer. Cancer Discovery, 2019, 9, 605-616.	9.4	11
29	Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 830.	7.4	11
30	Prognostic factors and survival in non-central nervous system rhabdoid tumors. Journal of Pediatric Surgery, 2017, 52, 373-376.	1.6	10
31	Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL. Blood, 2015, 126, 2533-2533.	1.4	10
32	Maintenance chemotherapy to reduce the risk of a metachronous Wilms tumor in children with bilateral nephroblastomatosis. Pediatric Blood and Cancer, 2019, 66, e27500.	1.5	6
33	Differential Impact of ALK Mutations in Neuroblastoma. JCO Precision Oncology, 2021, 5, 492-500.	3.0	6
34	A case ofKMT2Aâ€“SEPT9fusionâ€“associated acute megakaryoblastic leukemia. Journal of Physical Education and Sports Management, 2018, 4, a003426.	1.2	5
35	Successful treatment and integrated genomic analysis of an infant with FIP1L1-RARA fusionâ€“associated myeloid neoplasm. Blood Advances, 2022, 6, 1137-1142.	5.2	4
36	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Journal of Clinical Oncology, 2021, 39, 3822-3828.	1.6	4

#	Article	IF	Citations
37	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. Blood, 2018, 132, 261-261.	1.4	3
38	Acute myeloid leukemia with an fusion in a young child with Down syndrome.. Cold Spring Harbor Molecular Case Studies, 2022, 8, .	1.0	3
39	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. JCO Precision Oncology, 2020, 4, 1280-1284.	3.0	1
40	Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas. Sarcoma, 2021, 2021, 1-7.	1.3	1
41	Identification of a TP53 Deletion in an Undifferentiated Embryonal Sarcoma of the Liver Provides Clinically Relevant Longitudinal Detection of Circulating Tumor DNA. JCO Precision Oncology, 2021, 5, 1421-1425.	3.0	1
42	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Pediatric Patients with Treatment Related Myelodysplastic Syndrome or Acute Myelogenous Leukemia (tMDS/AML). Blood, 2010, 116, 2363-2363.	1.4	0
43	Phase II Trial of Clofarabine in Combination with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Pediatric Patients with Refractory or Relapsed Acute Leukemia. Blood, 2012, 120, 1514-1514.	1.4	0
44	Clofarabine with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Children and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 2018, 132, 79-79.	1.4	0